



09th November 2024

To
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers, 25th Floor,
Dalal Street,
Mumbai- 400001
Scrip Code - 543308
ISIN: INE967H01025

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
Symbol - KIMS
ISIN: INE967H01025

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 09th November 2024 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to our intimation dated 25th October 2024, the Board of Directors, at its meeting held today, has approved the unaudited (Standalone and Consolidated) financial results of the Company for the 02nd quarter and half-year ended 30th September 2024 together with the Limited Review Reports as reviewed by the Audit Committee.

The financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI \(LODR\) Regulations, 2015/ Financial Information/ Financial Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations,_2015/_Financial_Information/_Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com, respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at : 2.00 P.M.
Board Meeting Concluded at : 3.35 P.M.

This is for your information and records.

Thanking you,
For Krishna Institute of Medical Sciences Limited

MANTHA
SHANKER UMA

Digitally signed by
MANTHA SHANKER UMA
Date: 2024.11.09 15:40:12
+05'30'

Umashankar Mantha
Company Secretary & Compliance Officer
Enclosed: As above

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 24102328BKE202405840

Place Hyderabad

Date: November 09, 2024



Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2024

(Rupees in millions)

		Quarter ended			Half year ended		Year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations	3,633	3,274	3,162	6,907	6,151	12,221
	(b) Other income	66	53	36	119	74	155
	Total Income	3,699	3,327	3,198	7,026	6,225	12,376
2	Expenses						
	(a) Purchase of medical consumables, drugs and surgical instruments	691	645	672	1,336	1,329	2,536
	(b) Decrease/(increase) in inventories of medical consumables, drugs and surgical instruments	19	(10)	(11)	9	(54)	(29)
	(c) Employee benefits expense	596	615	559	1,211	1,093	2,196
	(d) Other expenses	1,216	1,086	960	2,302	1,878	3,874
	(e) Finance cost	46	38	1	84	1	36
	(f) Depreciation and amortisation expense	140	137	128	277	249	581
	Total Expenses	2,708	2,511	2,309	5,219	4,496	9,194
3	Profit before tax (1-2)	991	816	889	1,807	1,729	3,182
4	Tax expense						
	(a) Current tax	293	218	233	511	445	817
	(b) Deferred tax credit	(24)	(9)	(5)	(33)	(3)	(6)
	(c) Adjustment of tax relating to earlier periods/years	-	-	-	-	-	18
	Total tax expenses	269	209	228	478	442	829
5	Profit for the period/year (3-4)	722	607	661	1,329	1,287	2,353
6	Other comprehensive (loss)/income						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	(20)	1	3	(19)	5	3
	- Income tax effect	5	-	(1)	5	(1)	(1)
	Other comprehensive (loss)/income, net of tax	(15)	1	2	(14)	4	2
7	Total comprehensive income (5+6)	707	608	663	1,315	1,291	2,355
8	Paid up equity share capital (face value of Rs.2 each)						800
9	Other Equity						17,864
10	Earnings per share (of Rs.2 each) : (not annualised for the quarter/period ended)						
	(a) Basic (Rs.)*	1.80	1.52	1.65	3.32	3.22	5.88
	(b) Diluted (Rs.)*	1.80	1.52	1.65	3.32	3.22	5.88

*The equity shares of the Company of Rs. 10/- each has been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. September 13, 2024, accordingly EPS has been restated for all the periods.




Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2024 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 09 November 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Unaudited Standalone Balance sheet and Unaudited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- 4 The Board of Directors, at their meeting held on June 28, 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs. 10/- each into 5 equity shares of Rs. 2/- each), and the same has been approved by the shareholders in the Annual General Meeting of the Company held on August 29, 2024. The Company fixed the "record date" of September 13, 2024. Accordingly, equity shares of the Company of Rs. 10/- has been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. September 13, 2024 and earnings per equity share has been restated for all the periods.
- 5 During the current period, the Company acquired 100% of the equity share capital of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs. 1,112 Mn, consisting of Rs. 277 Mn towards purchase of shares and Rs. 835 Mn towards purchase of hospital land and building. Consequently, Queen's NRI Hospital has become a wholly owned subsidiary.
- 6 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 7 The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.




Hyderabad
09 November 2024

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited



Dr. B Bhaskara Rao
Managing Director
DIN: 00008985



Krishna Institute of Medical Sciences Limited


Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Unaudited Standalone Balance Sheet as at 30 September 2024

(Rupees in millions)

	Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
A	ASSETS		
1	Non-current Assets		
	Property, plant and equipment	6,333	6,265
	Capital work-in-progress	3,511	2,920
	Intangible assets	238	184
	Right-of-use assets	288	290
	Financial assets		
	(i) Investments	11,363	10,007
	(ii) Loans	2,063	958
	(iii) Other financial assets	183	100
	Non-current tax assets (net)	36	37
	Other non-current assets	686	193
	Total Non-current Assets - (1)	24,701	20,954
2	Current Assets		
	Inventories	212	221
	Financial assets		
	(i) Investments	-	616
	(ii) Trade receivables	1,822	1,487
	(iii) Cash and cash equivalents	179	205
	(iv) Bank balances other than (iii) above	41	-
	(v) Loans	47	92
	(vi) Other financial assets	285	235
	Other current assets	179	156
	Total Current Assets - (2)	2,765	3,012
3	Total Assets (3) = (1)+(2)	27,466	23,966
4	Equity and Liabilities		
	EQUITY		
	Equity share capital	800	800
	Other equity	19,179	17,864
	Total Equity - (4)	19,979	18,664
B	LIABILITIES		
5	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	3,716	2,572
	(ii) Other financial liabilities	159	100
	Provisions	219	191
	Deferred tax liabilities (net)	308	346
	Total Non-current liabilities - (5)	4,402	3,209
6	Current liabilities		
	Financial liabilities		
	(i) Borrowing	1,169	691
	(ii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	79	3
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,028	782
	(iii) Other financial liabilities	245	179
	Other current liabilities	348	336
	Provisions	106	102
	Current tax liabilities (net)	110	-
	Total Current liabilities - (6)	3,085	2,093
	Total Equity and Liabilities (7) = (4)+(5)+(6)	27,466	23,966



Krishna Institute of Medical Sciences Limited


Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/I, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Cashflows for the half year ended 30 September 2024

Particulars	(Rupees in millions)	
	For the half year ended	For the half year ended
	30-Sep-24 (Unaudited)	30-Sep-23 (Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	1,807	1,729
Adjustments for operating activities:		
Depreciation and amortisation expense	277	249
Profit on sale of property, plant and equipment	(3)	-
Expected credit loss for trade receivables (net of bad debts)	132	-
Guarantee commission income	(6)	(6)
Interest income	(76)	(45)
Liabilities no longer required written back	-	(3)
Gain on Mutual funds	(28)	(11)
Finance costs	84	1
Operating cash flows before working capital changes	2,187	1,914
Adjustments for:		
(Increase)/decrease		
- in trade receivables	(466)	(96)
- in inventories	9	(54)
- in other financial assets and other assets	(139)	(214)
Increase in trade payables, other financial liabilities, provisions and other liabilities	360	308
Cash generated from operations	1,951	1,858
Income taxes paid, net of refunds	(401)	(410)
Net cash generated from operating activities (1)	1,550	1,448
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(1,332)	(892)
Proceeds from sale of property, plant and equipment	10	-
Investment in subsidiaries	(1,307)	(502)
Investment in subsidiaries pending allotment	(79)	-
Investment in mutual funds	(950)	(740)
Proceeds from sale of mutual funds	1,594	730
Loans given to subsidiaries	(1,735)	(271)
Loans repaid by subsidiaries	675	80
Redemption of bank deposits (having original maturity of more than three months)	1	20
Investment in bank deposits (having original maturity of more than three months)	(40)	0
Interest received	135	8
Net cash flows used in investing activities (2)	(3,028)	(1,567)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	1,345	(42)
Repayment of long-term borrowings	(7)	-
Proceeds from short-term borrowings (net)	285	-
Interest paid	(171)	(1)
Net cash flows generated from/(used in) financing activities (3)	1,452	(43)
Net decrease in cash and cash equivalents (1+2+3)	(26)	(162)
Cash and cash equivalents at the beginning of the year	205	381
Cash and cash equivalents at the end of the period	179	219
Components of cash and cash equivalents		
Cash on hand	21	13
Balances with banks		
- On current accounts	152	206
- In deposit accounts	6	-
Total	179	219



[Handwritten signature]

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable

4. The Statement includes the results of the following entities:

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

S.No.	Entity	Relationship
10	Sarvejana Healthcare Private Limited	Subsidiary
11	Rajyalakshmi Healthcare Private Limited	Subsidiary
12	SPANV Medisearch Lifesciences Private Limited	Subsidiary
13	KIMS Manavata Hospitals Private Limited	Subsidiary
14	Meda Institute of Podiatry Private Limited *	Subsidiary
15	Chalasanani Hospitals Private Limited *	Subsidiary
16	Kondapur Healthcare Limited (Formerly known as RVM Healthcare Limited)	Associate

*Became a subsidiary during the current period.

- Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
 - Four subsidiaries, whose unaudited interim financial results include total assets of Rs. 2,242 million as at September 30, 2024, total revenues of Rs. 61 million and Rs. 61 million, total net loss after tax of Rs. 13 million and Rs. 14 million, total comprehensive loss of Rs. 13 million and Rs. 14 million for the quarter ended September 30, 2024 and the period ended on that date respectively, and net cash inflows of Rs. 29 million for the period from April 01, 2024 to September 30, 2024, as considered in the Statement which have been reviewed by their respective independent auditors.
 - An associate whose unaudited interim financial results include Group's share of net loss of Rs. Nil and Rs. Nil and Group's share of total comprehensive loss of Rs. Nil and Rs. Nil for the quarter ended September 30, 2024 and for the period from April 01, 2024 to September 30, 2024 respectively, as considered in the Statement whose interim financial results and other financial information has been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

Navneet Rai →

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 24102328

Place: Hyderabad

Date: November 09, 2024



BKE 2 QH 3780

Statement of Unaudited Consolidated Financial Results for the Quarter and half year ended 30 September 2024

		Quarter Ended			Half year ended		Year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
(Rupees in millions)							
1	Income						
	(a) Revenue from operations	7,773	6,884	6,525	14,657	12,585	24,981
	(b) Other income	50	46	29	96	60	131
	Total Income	7,823	6,930	6,554	14,753	12,645	25,112
2	Expenses						
	(a) Purchase of medical consumables, drugs and surgical instruments	1,566	1,448	1,425	3,014	2,772	5,369
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(11)	(22)	(21)	(33)	(68)	(66)
	(c) Employee benefits expense	1,192	1,186	1,057	2,378	2,096	4,224
	(d) Other expenses	2,845	2,478	2,291	5,323	4,442	9,051
	(e) Finance costs	199	179	89	378	182	470
	(f) Depreciation and amortisation expenses	410	390	326	800	649	1,465
	Total Expenses	6,201	5,659	5,167	11,860	10,073	20,513
3	Profit before share of loss from associate (1-2)	1,622	1,271	1,387	2,893	2,572	4,599
4	Share of loss from associate, net of tax	-	-	(0)	-	(0)	(3)
5	Profit before tax (3+4)	1,622	1,271	1,387	2,893	2,572	4,596
6	Tax expense						
	(a) Current tax	448	338	363	786	682	1,162
	(b) Deferred tax (credit)/charge	(35)	(19)	2	(54)	2	40
	(c) Adjustment of tax relating to earlier periods/years	2	-	9	2	9	34
	Total tax expenses (6)	415	319	374	734	693	1,236
7	Profit for the period/year (5-6)	1,207	952	1,013	2,159	1,879	3,360
	Attributable to:						
	Owners of the company	1,074	866	920	1,940	1,728	3,101
	Non controlling interests	133	86	93	219	151	259
8	Other comprehensive (loss)/ income for the period/year						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	(31)	1	3	(30)	5	4
	- Income tax effect	8	-	(1)	8	(1)	(1)
	Other comprehensive (loss)/ income, net of tax	(23)	1	2	(22)	4	3
	Attributable to:						
	Owners of the company	(20)	1	2	(19)	4	3
	Non controlling interests	(3)	-	-	(3)	-	-
9	Total comprehensive income (7+8)						
	Owners of the company	1,054	867	922	1,921	1,732	3,104
	Non controlling interests	130	86	93	216	151	259
	Total comprehensive income	1,184	953	1,015	2,137	1,883	3,363
10	Paid up equity share capital (face value of Rs.2 each)						800
11	Other Equity						17,483
12	Earnings per share (of Rs.2 each): (not annualised for the quarter and period ended)						
	(a) Basic (Rs.)*	2.68	2.16	2.30	4.85	4.32	7.75
	(b) Diluted (Rs.)*	2.68	2.16	2.30	4.85	4.32	7.75

*The equity shares of the Company of Rs.10/ has been sub-divided into 5 equity shares of Rs.2/- each w.e.f. September 13,2024, accordingly EPS has been restated for all the periods.



Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2024 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") and its associate has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 9 November 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Unaudited Consolidated Balance sheet and Unaudited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- 4 The Board of Directors, at their meeting held on June 28, 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs. 10/- each into 5 equity shares of Rs. 2/- each), and the same has been approved by the shareholders in the Annual General Meeting of the Company held on August 29, 2024. The Company fixed the "record date" of September 13, 2024. Accordingly, equity shares of the Company of Rs. 10/- has been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. September 13, 2024 and earnings per equity share has been restated for all the periods.
- 5 During the current period, Group acquired 100% of the equity share capital of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs. 1,112 Mn, consisting of Rs. 277 Mn towards purchase of shares and Rs. 835 Mn towards purchase of hospital land and building. Consequently, Queen's NRI Hospital has become a wholly owned subsidiary. The transaction was accounted in accordance with Ind AS-103-Business Combinations ("Ind AS 103") and the initial accounting was provisionally determined as at 30 September 2024.
- 6 The Group operates in one single reportable business segment- "Medical and Healthcare services".
- 7 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.



Hyderabad
09 November 2024



For and on behalf of the Board
Krishna Institute of Medical Sciences Limited

Dr. B Bhaskara Rao
Managing Director
DIN: 00008985

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Consolidated Unaudited Balance Sheet as at 30 September 2024

(Rupees in millions)

S.No	Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
A	ASSETS		
1	Non current Assets		
	Property, plant and equipment	18,470	17,300
	Capital work-in-progress	8,540	6,001
	Goodwill	3,787	3,080
	Other Intangible assets	665	646
	Right-of-use assets	3,398	3,312
	Financial assets		
	(i) Investments in Associate	765	738
	(ii) Other Investments	6	6
	(iii) Loans	650	260
	(iv) Other financial assets	812	350
	Deferred tax asset (net)	327	319
	Non-current tax assets (net)	515	455
	Other non-current assets	1,600	578
	Total Non current Assets - (1)	39,535	33,045
2	Current Assets		
	Inventories	540	494
	Financial assets		
	(i) Investments	133	830
	(ii) Trade receivables	3,885	2,944
	(iii) Cash and cash equivalents	632	469
	(iv) Bank balances other than (iii) above	137	21
	(v) Other financial assets	507	358
	Other current assets	418	358
	Total Current Assets - (2)	6,252	5,474
3	Total Assets (3) = (1)+(2)	45,787	38,519
B	LIABILITIES		
4	EQUITY AND LIABILITY		
	Equity share capital	800	800
	Other equity	19,220	17,483
	Equity attributable to Shareholders of the company - (4)	20,020	18,283
5	Non-controlling interests - (5)	2,808	2,649
6	Total Equity (6) = (4)+(5)	22,828	20,932
7	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	12,471	9,276
	(ii) Lease liabilities	3,130	2,987
	(iii) Other financial liabilities	103	65
	Provisions	326	274
	Deferred tax liabilities (net)	347	463
	Total Non-current liabilities - (7)	16,377	13,065
8	Current liabilities		
	Financial liabilities		
	(i) Borrowings	2,069	1,186
	(ii) Lease liabilities	153	104
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	200	125
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,513	1,846
	(iv) Other financial liabilities	842	611
	Provisions	197	186
	Other current liabilities	493	464
	Current tax liabilities (Net)	115	-
	Total Current liabilities - (8)	6,582	4,522
9	Total Equity and Liabilities (9) = (6)+(7)+(8)	45,787	38,519



Manu

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Cash flows for the half year ended 30 September 2024

(Rupees in millions)

Particulars	For the half year ended	For the half year ended
	30-Sep-24	30-Sep-23
	(Unaudited)	(Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	2,893	2,572
Adjustments for operating activities:		
Depreciation and amortisation expenses	800	649
Finance costs	378	182
Loss/(Profit) on sale of property, plant and equipment (net)	13	(1)
Expected credit loss for trade receivables (net of bad debts)	201	14
Interest income	(39)	(8)
Liabilities no longer required written back	-	(5)
Gain on mutual funds	(35)	(22)
Rental income	(2)	(2)
Operating cash flows before working capital changes	4,209	3,379
Adjustments for:		
(Increase)/Decrease		
- In Trade receivables	(935)	(151)
- in Inventories	(33)	(68)
- in Other financial assets and other assets	(701)	(198)
Increase in trade payables, other financial liabilities, provisions and other liabilities	597	478
Cash generated from operations	3,137	3,440
Income taxes paid, net of refunds	(676)	(732)
Net cash generated from operating activities (1)	2,461	2,708
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(3,750)	(2,850)
Proceeds from sale of property, plant and equipment	21	4
Investment in subsidiaries and associate	(1,150)	(500)
Investment in mutual funds	(1,540)	(1,925)
Proceeds from sale of mutual funds	2,271	1,970
Loans given to an associate	(390)	-
Redemption of bank deposits (having original maturity of more than three months)	22	20
Investment in bank deposits (having original maturity of more than three months)	(186)	(5)
Lease income received	2	2
Interest received	5	5
Net cash used in investing activities (2)	(4,695)	(3,279)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	3,217	1,222
Repayment of long-term borrowings	(115)	(80)
Proceeds from/(repayment of) short-term borrowings (net)	310	(16)
Acquisition of non-controlling interest	(332)	(417)
Payment of principal of lease liability	(16)	(25)
Payment of interest on lease liability	(141)	(99)
Interest paid	(530)	(251)
Net cash flows generated from financing activities (3)	2,393	334
Net Increase/(decrease) in cash and cash equivalents (1+2+3)	159	(237)
Cash and cash equivalents acquired through business combination	4	-
Cash and cash equivalents at the beginning of the year	469	616
Cash and cash equivalents at the end of the period	632	379
Components of cash and cash equivalents		
Cash on hand	41	21
Balances with banks		
- On current accounts	310	349
- In deposit accounts (with original maturity of 3 months or more)	281	9
Total	632	379



[Handwritten signature]